30.04.2018 • News • biologics • Catalent • Pharmaceuticals

Catalent Biologics Restructures Biologics Business

Tedd Green, former president of Cook Pharmica, has been appointed as senior...
Tedd Green, former president of Cook Pharmica, has been appointed as senior vice president of Catalent Biologics.

US drugmaker Catalent announced key organizational changes within its biologics business.

Tedd Green, former president of Cook Pharmica, has been appointed as senior vice president of Catalent Biologics, and will have responsibility for the entire biologics business. In this role he will also act as a member of Catalent’s executive leadership team. Green will be based at the Bloomington facility.

Mike Riley has been appointed as vice president and general manager of Drug Substance and Bioanalytical services for Catalent Biologics. He will lead the company’s biologics manufacturing business based at several sites across Catalent’s global network.

Cory Lewis will take on the new role of vice president and general manager of the company’s Drug Product business, with a focus on growing the drug product offerings both in the US and in Europe.

In a further move, Ryan Hawkins has been appointed as general manager of the Bloomington site.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.